Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Perinatal Stroke: Understanding Brain Reorganization
Stroke · Hemiparesis
Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV
Phase 2 N=122 Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)
Severe Traumatic Brain Injury
Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion
Phase 1 N=20 Reperfusion With Cooling in Cerebral Acute Ischemia
Stroke, Acute
Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants
N/A N=35 Neural Bases of Cognitive Rehabilitation for Brain Injury
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
N/A N=1 Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging
Traumatic Brain Injury · Multiple Sclerosis · Alzheimer's Disease
Primary: Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI. — 35.4 ml/100g/min
N/A N=25 Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage
Intracerebral Hemorrhage · Acute Ischemic Stroke
Primary: Change in Interleukin-1beta Level in Blood (Picogram/Milliliter)
N/A N=31 Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke
Stroke
Primary: Changes in Brain Activation — 48.5; -30 voxels
Phase 3 N=13 Inhaled Nitric Oxide in Brain Injury
Traumatic Brain Injury
Primary: PaO2 — 115; 95 mmHg — p=<0.05
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
N/A N=40 Effects of Biofeedback in Patients With Acute Cerebral Infarction
Acute Ischemic Stroke · Biofeedback · Autonomic Dysfunction, Cognitive Function
Primary: Changes From Baseline Psychological Distress (Anxiety and Depression) at 1 and 3 Months — 14.74; 14.75; 13.11; 14.25 score on a scale
N/A N=146 Imaging Guided Patient Selection for Interventional Revascularization Therapy
Acute Ischemic Stroke
Primary: Functional Outcome as Defined by a mRS of 0-2 at 90 Days Post-procedure — 57 Participants
Phase 2 N=10 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Radiation Necrosis
Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012
Phase 2 N=84 Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
Acute Cerebral Stroke Within 12 Hours for the First Time
Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale
Phase 2 N=161 Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 2 N=18 Hyperbaric Treatment of Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Number of Participants With Improved Cerebral Perfusion — 8 Participants
N/A N=126 Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Cerebrovascular Accident · Moyamoya Disease
Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…
Phase 2 N=103 The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
Cerebrovascular Disease
Primary: Blood Pressure and Heart Rates;
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
N/A N=12 MRI for Non-invasive Evaluation of Brain Stress
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
N/A N=2,839 The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
Intracerebral Hemorrhage · Stroke · Hypertension
Primary: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) — 719; 785 participants
Phase 2 N=19 Intranasal Insulin and Post-stroke Cognition: A Pilot Study
Stroke
Primary: Composite of Memory t Scores — 39.5; 39.7 score on a scale
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
N/A N=3 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
Stroke, Ischemic · Inflammatory Response · Stroke, Acute
Primary: Changes in TSPO Radiotracer Uptake Infarct Area — 1.54 g/mL
Phase 2 N=256 Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury
Intraventricular Hemorrhage · Periventricular Leukomalacia · Brain Injury
Primary: Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL — 22.2; 14.9; 17.1; 10.9 percent of participants
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
N/A N=17 Brain Biomarkers of Response to Treatment for Apraxia of Speech
Aphasia · Stroke
Primary: Change From Baseline in Percent of Trained Items Correctly Repeated — 6.67 d2 treatment effect size